Designing the First Trials for Parkinson’s Prevention
Journal of Parkinson’s Disease · 01.10.2024 · 14 (s2) · S381-S393
DOI: 10.3233/jpd-240164 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Parkinson’s Disease, online erschienen am 18.09.2024. Verfasst von Grace F Crotty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Char…. Hauptthemen laut MEDLINE: Parkinson Disease, Prodromal Symptoms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: FDA HHS.
Abstract (Originalsprache)
For decades the greatest goal of Parkinson’s disease (PD) research has often been distilled to the discovery of treatments that prevent the disease or its progression. However, until recently only the latter has been realistically pursued through randomized clinical trials of candidate disease-modifying therapy (DMT) conducted on individuals after they received traditional clinical diagnosis of PD (i.e., tertiary prevention trials). Now, in light of major advances in our understanding of the prodromal stages of PD, as well as its genetics and biomarkers, the first secondary prevention trials for PD are beginning. In this review, we take stock of DMT trials to date, summarize the breakthroughs that allow the identification of cohorts at high risk of developing a traditional diagnosis of PD, and describe key design elements of secondary prevention trials and how they depend on the prodromal stage being targeted. These elements address whom to enroll, what interventions to test, and how to measure secondary prevention (i.e., slowed progression during the prodromal stages of PD). Although these design strategies, along with the biological definition, subtype classification, and staging of the disease are evolving, all are driven by continued progress in the underlying science and integrated by a broad motivated community of stakeholders. While considerable methodological challenges remain, opportunities to move clinical trials of DMT to earlier points in the disease process than ever before have begun to unfold, and the prospects for PD prevention are nowtangible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Neurobiology Laboratory, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Present address: Department of Neurology, Cork University Hospital, Cork, Ireland.
Förderung
- FDA HHS
Zitieren
APA
Crotty, G. F., Ayer, S. J., & Schwarzschild, M. A. (2024). Designing the First Trials for Parkinson’s Prevention. Journal of Parkinson’s Disease, 14(s2), S381-S393. https://doi.org/10.3233/jpd-240164
Vancouver
Crotty GF, Ayer SJ, Schwarzschild MA. Designing the First Trials for Parkinson’s Prevention. Journal of Parkinson’s Disease. 2024;14(s2):S381-S393. doi:10.3233/jpd-240164
BibTeX
@article{Crotty2024,
author = {Crotty, Grace F and Ayer, Samuel J and Schwarzschild, Michael A},
title = {Designing the First Trials for Parkinson’s Prevention},
journal = {Journal of Parkinson’s Disease},
year = {2024},
volume = {14},
number = {s2},
pages = {S381--S393},
doi = {10.3233/jpd-240164}
}
EUVIMED